S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

SQZ Biotechnologies Stock Forecast, Price & News

+1.16 (+9.67%)
(As of 11/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
115,709 shs
Average Volume
143,888 shs
Market Capitalization
$369.36 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SQZ News and Ratings via Email

Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SQZ Biotechnologies logo

About SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.


SQZ: Something New to Squeeze Into Your Portfolio
November 30, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Year Founded

Sales & Book Value

Annual Sales
$21 million
Book Value
$4.75 per share


Net Income
$-50.52 million
Net Margins
Pretax Margin




Free Float
Market Cap
$369.36 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.33 out of 5 stars

Medical Sector

1134th out of 1,390 stocks

Biological Products, Except Diagnostic Industry

169th out of 202 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

SQZ Biotechnologies (NYSE:SQZ) Frequently Asked Questions

Is SQZ Biotechnologies a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SQZ Biotechnologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SQZ Biotechnologies stock.
View analyst ratings for SQZ Biotechnologies
or view top-rated stocks.

When is SQZ Biotechnologies' next earnings date?

SQZ Biotechnologies is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for SQZ Biotechnologies

How were SQZ Biotechnologies' earnings last quarter?

SQZ Biotechnologies (NYSE:SQZ) posted its earnings results on Wednesday, November, 10th. The company reported ($0.80) EPS for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.24. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 51.18% and a negative net margin of 432.38%.
View SQZ Biotechnologies' earnings history

Who are SQZ Biotechnologies' key executives?

SQZ Biotechnologies' management team includes the following people:
  • Dr. Armon R. Sharei, Co-Founder, Pres, CEO & Director (Age 34, Pay $692.57k)
  • Ms. Teri Loxam, Chief Financial Officer (Age 49, Pay $633.03k)
  • Mr. Lawrence J. Knopf, Gen. Counsel & Sec. (Age 59, Pay $474.45k)
  • Dr. Oliver Rosen, Chief Medical Officer (Age 57, Pay $557.29k)
  • Mr. Micah Zajic, Chief Bus. Officer (Age 40, Pay $288.65k)
  • Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 72)
  • Dr. Howard Bernstein, Chief Scientific Officer (Age 64)
  • Mr. David First, Chief People Officer (Age 57)

When did SQZ Biotechnologies IPO?

(SQZ) raised $75 million in an initial public offering on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel served as the underwriters for the IPO and BTIG was co-manager.

What is SQZ Biotechnologies' stock symbol?

SQZ Biotechnologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "SQZ."

Who are SQZ Biotechnologies' major shareholders?

SQZ Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Temasek Holdings Private Ltd (9.83%), 683 Capital Management LLC (6.03%), BlackRock Inc. (4.46%), Maverick Capital Ltd. (3.77%), Geode Capital Management LLC (0.92%) and Bank of New York Mellon Corp (0.25%).

Which major investors are selling SQZ Biotechnologies stock?

SQZ stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, California State Teachers Retirement System, New York State Common Retirement Fund, and SG Americas Securities LLC.

Which major investors are buying SQZ Biotechnologies stock?

SQZ stock was purchased by a variety of institutional investors in the last quarter, including 683 Capital Management LLC, Temasek Holdings Private Ltd, Maverick Capital Ltd., BlackRock Inc., ACT Capital L.L.C., Geode Capital Management LLC, Two Sigma Investments LP, and Bank of New York Mellon Corp.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SQZ Biotechnologies' stock price today?

One share of SQZ stock can currently be purchased for approximately $13.16.

How much money does SQZ Biotechnologies make?

SQZ Biotechnologies has a market capitalization of $369.36 million and generates $21 million in revenue each year.

How many employees does SQZ Biotechnologies have?

SQZ Biotechnologies employs 98 workers across the globe.

What is SQZ Biotechnologies' official website?

The official website for SQZ Biotechnologies is www.sqzbiotech.com.

Where are SQZ Biotechnologies' headquarters?

SQZ Biotechnologies is headquartered at 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472.

How can I contact SQZ Biotechnologies?

SQZ Biotechnologies' mailing address is 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472. The company can be reached via phone at 617-758-8672 or via email at [email protected].

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.